112 Years Old
... Still the Life of the Party

Your grandparents would have called it impossible. But it’s happening right now.

Nearly miraculous advances in biotechnology are going to bring you unexpected years of long life and vigorous good health. A decade from now, you may look, feel, and in fact be healthier than you are today.

100th birthdays are going to be commonplace. Don’t worry. When the time comes to celebrate yours, you won’t be a wrinkled prune—and you won’t have to huff and puff to blow out all those candles.

I know. I’ve already tapped into an early sample of the science that will do so much to extend our lifespans. It works. I just turned 64, and by any objective standard—energy, stamina, flexibility, mental acuity, productivity, general fitness—I’m in better shape now than I was a dozen years ago.

You may soon be able to say the same about yourself. Eventually, millions of other people will be saying it, too.

Health Spans Will Soon Reach 120

The extension of healthy lifespans won’t just be mankind’s greatest victory of the 21st century—it may well be the most profitable.

Much of that profit will flow to small, fast-moving biotech companies and be captured by the early investors who act on a reality most haven’t yet noticed: the old business of treating disease is being pushed aside by the new business of slowing aging.

Institutional investors are just starting to wake up to the high profit potential of the companies I study. Many of the best stocks are still cheap, so there’s still room for rapid, triple-digit appreciation—or more.

And I gain an extra benefit from an up-close monitoring of the progress of anti-aging technology.

When I talk one on one with leading biotech researchers, it’s not just about theory. The conversation always finds its way back down to Earth. That’s when they tell me how they’re already applying their discoveries for their own good health and longevity.

I listen. Then I use what I learn. I use it every day. And I’d like to share it with you.

This is your opportunity to share in the continuing knowledge flow about health, life extension, and winning investments. To capture what could be the richest run of investment success you’ll ever enjoy... in what I expect to be your wonderfully long life.

Longevity... vigorous good health... financial abundance. No thoroughbred ever ran a richer trifecta. This is one I know you’d like to win. My job is to show you how.

To Win with Biotech Stocks, You Need to Be Picky

Look for companies that, first of all, are serious about science. I’m not interested in health-food fads or bigger vitamin pills or another weight-loss gizmo.

To catch my attention, a project should be driven by PhDs in biochemistry, cellular biology, and other hard sciences. (Advanced degrees in aromatherapy or veganism won’t do.) And the company must have a clear-eyed plan for turning its technical prowess into money.

When I find a biotech stock with that profit duo—revolutionary science plus business smarts—I dig in to learn more.

I want to know all about what they are doing in the lab, I want to know all about the good they are preparing for mankind, I want to know all about their business strategy and their financial strength, and I want to know all about the big, big numbers they are going to take to the bank.

I speak almost daily with the biotech geniuses and entrepreneurs who run the strongest of these companies—the ones that have stacked the deck in favor of large-scale financial success. They’ve got my attention because I love science and because I want to share in the Google-size payoff that’s already enriching biotech investors who do their homework. So I study them 24/7.

We’re Going to Slow Aging to a Crawl

Coming to you from the high-tech laboratories of Berkeley, Palo Alto, Cambridge, Winston-Salem, and other centers of cutting-edge science are weapons to defeat all the deadly infectious diseases most of us can name. Influenza, Ebola, malaria, flesh-eating bacteria—the entire repertoire of infectious human misery—soon will be hard to find outside of medical history books.

Welcome as that progress is going to be, it’s really just a sideshow.

Think about the diseases that take down the most victims—cancer, heart disease, stroke, Alzheimer’s, diabetes, arthritis, fibrotic liver disease. It’s rare for a 16-year-old to suffer from any of them.

But when you hear that an 80-year-old has been mugged by a stroke or crippled by arthritis, or has lost memory and self to Alzheimer’s, even though the bad news saddens you, it doesn’t shock. You make sense of it by thinking, “He’s 80, he’s old.”

That kind of thinking will soon be outdated. New and radically more effective treatments for each of those diseases of aging are in clinical trials today, even though the progress is mostly invisible to the public. Others are in earlier stages of research and development. But the nearly miraculous results they’ve shown so far are just the first chapter of the story science is writing.

Behind those one-by-one miracles is a strategy for extended health spans that is even more radical than any of the separate therapies: eliminate the diseases of old age by slowing the aging process itself. Slow it to a crawl.

Slowing aging to a crawl will hold all the diseases of aging at arm’s length until (no hard feelings if you don’t believe this at first) about age 100… and then 120.

That’s not a number I made up. I’ll explain how science found it. But first, two big-money questions I hope you’ll weigh carefully.

Q1. How much would you pay to enjoy vigorous good health all the way to age 120? No arthritis, no clogged arteries, no cancer, no joints that won’t go, no fading of mental sharpness. Just life. Full, healthy life at 60 beats per minute.

Q2. How much could you earn by delivering the same result to the other 8 billion people on the planet who dread the approach of infirmity and death?

Why So Many People Will Live Past Age 100...
...and Can Make You Rich as They Do

A little schoolwork. You’re going to get an “A” you can take to the bank.

Your body is made up of roughly 100 trillion cells. That’s a big number. If each of those cells were a sun, you’d be your own galaxy.

But they’re not suns. They are far more complex.

Any physical problem you might suffer means something is going wrong inside billions (or maybe trillions) of those cells. That’s all there is to any health problem, whether it’s an identifiable disease or simply feeling old and worn out.

The story of your cells is the whole and complete story of your health. Control the molecular life of your cells, and you control all of physical health.

In pre-modern times, medical practitioners knew none of that.

They had little to offer—just a few techniques for easing symptoms and only guesses about causes. Then, over about the last three centuries, the microscope, the germ theory, and analytical chemistry brought us most of the improvements of modern medicine.

Spectacular—nearly magical—as those results would seem to the inhabitants of the 1700s, they are really only a prelude to what’s coming. That prelude has already turned healthcare into the developed world’s biggest industry, with high-profit giants like Novartis, Glaxo Smith-Cline, Pfizer, Abbott Labs, and Eli Lilly raking in billions every year.

Those giants of today risk being the dinosaurs of tomorrow. They’re vulnerable because they’re still focused on treating disease rather than on slowing the aging that invites disease.

The 3 Vectors of Aging and How We’re About to Beat Them

In a moment, I’ll tell you how to get and use some of this new knowledge for your own good health and longevity, without waiting for the FDA’s multi-year regulatory process to play out one therapy at a time. And I’ll mention a few of the investment successes biotech progress has already delivered for myself and my readers.

But it will all make more sense if I start from a few steps back.

Three vectors of aging drive all the age-related diseases—cancer, heart disease, stroke, Alzheimer’s, diabetes, arthritis, macular degeneration, fibrotic liver disease. The process of aging is also implicated in obesity, which is aging’s closest companion.

Watch how each vector of aging speeds up the others. You’ll see the trap mankind has always been in—until now.

Aging Vector 1: Losing Your Supply of Telomeres

When your cells are young and mostly healthy, they divide, on average, about once per year to replace the ones that have died off. But as cellular damage from small mutations and other molecular mishaps accumulates, the healthier cells are forced to divide more frequently to provide replacements.

Cell division is not a freebie. It costs. It costs big. And nature has you on a budget.

For a cell to divide, each of its 46 double-stranded chromosomes must unzip temporarily to generate a copy of itself. To help them zip back up correctly, each chromosome is stabilized at one end by a long lasso of repeating proteins called a telomere.

You started life with about enough telomere sequence in many cells to replicate 120 times—but each time a cell divides, it loses one telomere sequence. And they don’t grow back. On average, a chromosome sheds about one telomere segment per year when we are young, but that accelerates as we age in part because our telomere sequences have shortened.

Every one of us is living on a telomere budget that nature will never refresh.

Telomere shrinkage hurts a chromosome’s ability to re-zip correctly. Clumsy re-zipping leaves the resulting cells less healthy and vigorous. Over time, division by division and one telomere segment loss at a time, damaging mishaps become more frequent... and you become more vulnerable to cancer, heart disease, stroke, Alzheimer’s, and the other diseases of aging.

If nothing else killed you, running out of telomere segments would. On the other hand, if none of your cells ever suffered any damage that sped up the spending of telomeres, you would live in good health to about age 120.

A small biotech company I track has developed technology that enables a cell to recover lost telomere segments.The result is cells as healthy, fresh, and vigorous as those of a newborn.

The technology has been successfully tested in animals and, in Japan, could soon be used to extend the lives of wealthy humans.

This is a history-shaking topic. And it’s going to be a profit-spouting reality. My readers have already collected in a big way and put the money in their pockets, as you’ll read about below. But there is much, much more to come from the right companies in this field.

I’ll tell you more about it later in this letter. And when I do, I’ll show you a piece of real science that is more astounding than science fiction. It’s something so wonderful, you’ll wish you could have it for yourself. Soon you can.

Aging Vector 2: Mitochondrial Confusion

Hard at work in most of your body’s 100 trillion cells are legions (some cells have thousands) of mitochondria. Each of them is a microscopic power plant that burns glucose from the food you eat to deliver energy the cell can use directly.

A cell’s energy needs fluctuate constantly. To help the mitochondria respond efficiently, a cell is equipped with a real-time, internal communication system that tells mitochondria when to “fire up” or “cool down.” That signaling depends on the coenzyme nicotinamide adenine dinucleotide—whose short name is NAD⁺.

Unfortunately, the natural availability of the NAD⁺ signaling molecule drops off with age. And as it does, the cell drifts toward confusion. Mitochondria lose touch with the cell’s fluctuating power needs. The cell’s energy supply flutters unresponsively.

That hurts everything the cell does—including its self-repair functions. Cellular damage from mutations and other mishaps is left to accumulate like trash no one bothers to take out. Your vulnerability to cancer, heart disease, Alzheimer’s, and other catastrophic diseases increases day by day. Obesity, aging’s closest companion, becomes harder to escape.

This deterioration goes on in all of your cells, so everything about your body works less well. Mistakes don’t get repaired the way they did when you were younger.

And because more and more damaged cells need to be replaced, the healthier cells must divide more frequently. The spending of those 120 telomere segments speeds up. In other words, aging accelerates.

A biotech innovator I follow has developed technology for restoring communication between mitochondria and the rest of the cell to full, loud, youthful clarity. The stock is high up on my buy list.

You don’t have to wait for FDA approval (often a 10-year legal ordeal) to start exploiting the basis of this new technology for your own health. There are naturally occurring substances, well studied in the lab but occurring in nature, that you can use now to restore the youthful performance of your mitochondria.

You’ll feel better, and you’ll in fact be healthier. You’ll steer your own aging toward the slow lane.

That’s the kind of health and profit information I’d seek out just for my own well-being. But it’s not just for me. Everything I find, I share with the readers of my newsletter.

Aging Vector 3: Chronic Inflammation

Your immune system responds to infection by wrapping you in a biochemical blanket of inflammation. In 2011, cell biologist Ralph Steinman of Rockefeller University shared the Nobel Prize in Medicine for discovering how inflammation normally works to protect you but how it can turn into a threat when you get older.

At least while you’re young, inflammation helps repair cells damaged by infection. And it sweeps away the cells that can’t be fixed.

The trigger for all that urgent maintenance work is a protein called Nuclear factor kappa B (NfkB). When the work is finished, NfkB production automatically shuts down and inflammation turns off. Or it should. And when you’re young, it does, and it does so promptly and reliably. But then...

With age, each time NfkB is activated, it hangs around longer and longer. It persists even after it’s done all the good it can. Eventually, low-level inflammation becomes chronic. From there on, it hurts more than it helps.

Why don’t you feel as strong and vigorous as you used to? Because the NfkB fix-it molecule won’t go back to its cubicle, sit quietly, and wait for the next real job. It sees your healthy cells as problems that need to be dealt with. With nothing else to do, your immune system goes to war with you.

Now you know where arthritis and the other auto-immune diseases come from.

Artery blockage comes from the same place. Inflammation robs the inner surfaces of your arteries of the wet-ice slickness they were born with. They develop Velcro-like scars that stick out and snag cholesterol from your blood. The collected mess turns into plaques, which narrow your arteries and force your heart to pump harder and harder.

And it’s not just your heart. Chronic inflammation, like mitochondrial sputtering, stresses every cell in your body. That means more frequent cell division and even faster spending of telomere segments. Remember, living on a telomere budget that nature will never refresh.

A biotech developer I introduced to my readers is running Phase-1 trials on a naturally occurring plant molecule that reduces over-production of NfkB and lets inflammation turn off when it should. The substance works beautifully in test animals. And in the recent past, before the FDA decided to call it a pharmaceutical, it was used safely by more than 100,000 people in the US.

When it again becomes available, it may do more to carry an arthritis-free you to age 120 than any other single therapy.

Untroubled by self-destructive inflammation, the insides of your arteries would begin to regain their original, shiny smoothness. There’d be less to snag cholesterol. You’d tolerate cheeseburgers like a 16-year-old.

My readers will be first in line.

Any one of those vectors of aging—telomere loss, mitochondrial dysfunction, or chronic inflammation—would do you in eventually, even if nothing else went wrong. But setting up other things to go wrong—cancer, heart disease, stroke, Alzheimer’s, diabetes, arthritis, macular degeneration, fibrotic liver disease—is exactly what the three vectors of aging do.

Their most fearsome project is cancer. Until very recently, the only treatments were the brute-force therapies of surgery, radiation, and chemotherapy. They were nearly as rough on the patient as on the cancer itself. And for all the body slamming they did, they only bought a little time.

That’s changing. New knowledge about the chemical life of the cell is yielding treatments that will destroy a tumor without injuring the patient.

A private pharmaceuticals company I’ve been following is developing a new tumor-killing technology that has the power to change everything about treating cancer.

Our cells all have a built-in self-destruct mechanism. Abnormal cells set themselves up for death and in doing so let the immune system know it can pass them by. It’s our cells’ way of taking care of their own demise and helping to keep the body healthy.

Cancer cells are like zombie cells in that they’ve forgotten how to die. They trick the immune system by masquerading as an abnormal cell that has activated its self-destruct mechanism. This way, the immune system passes them by and they continue to live and multiply.

This company’s technology gives cancer cells a second chance to die. It is essentially melting cancer from within.

Bringing this new therapy to market could deliver a big home run for its investors.

Reversing Aging—the Boldest Biotech Endeavor

Technology now being perfected won’t just slow aging. It will undo aging. I’ve seen it work.

Your body began as a single cell. During the first five days of life, that Cell Number One spawned a clump of a few dozen cells, all identical. They had what none of your cells have today: a full set of damage-preventing, damage-fixing telomeres.

They were the start of you, but they were still unspecialized, with no particular functions. Every one of them had the full potential to be a skin cell, a brain cell, a heart cell, a liver cell, a retina cell, or any other type of human tissue.

In the language of genetics, those earliest cells were pluripotent. Then one by one, as the appropriate genes turned on or off, they developed the characteristics of skin, brain, heart, etc., and assembled themselves to be your body.

That’s how you arrived. And on arrival, every one of your cells was still untouched by the damage time brings and was fully healthy, robust, and shock-resistant.

You must have been a beautiful baby. But since then the clock has been running. Billions of tiny cellular mishaps have been accumulating.

If you’re much past age 29, those mishaps are making you detectably slower, weaker, stiffer, and probably somewhat heavier. Day by day, they are turning you into an easier and easier mark for cancer, heart disease, stroke, arthritis, Alzheimer’s... all the diseases of aging.

Sounds grim. And for mankind it always has been that grim, until now.

Rejuvenating Your Body with Pluripotent Cells

You are living at the first time in history when it makes sense to shout STOP to aging. Survive another 10 years or so (much of what I cover in Transformational Technology Alert focuses on that near-term goal), and science now far along in development will let you turn the clock back and purge yourself of all the cellular mishaps that make a person old.

Methods now being perfected in laboratories in Japan (under Nobel laureate Dr. Shinya Yamanaka), Israel, and the US will reenact the earliest hours of your life. You’ll acquire fresh cells to repair any organ or tissue that has been damaged by age. Here’s how the technology works:

Step 1. Remove a small number of cells from your body. They can be any type of cell, but skin cells are the easiest to reach.

Step 2. Treat them (there’s more than one method) to switch on the genes that marked the first few hours of your life. The cells become non-specialized, pluripotent, and endowed with full-length (120-segment) telomeres. They are identical to the cells of early embryonic you.

Step 3. Bathe the pluripotent cells in a chemical environment that promotes division, to grow large numbers of cells.

Step 4. Treat the resulting large population of pluripotent cells to turn on or off the genes that mark a particular type of cell—say, heart muscle cells.

Step 5. Return the specialized cells to your body.

It’s all science, but after Step 5, something happens that makes me want to sing a song of praise and celebration for the human genome. And dance to the music.

With no help from anyone, the engineered cells find their own way to your heart and incorporate themselves into your heart muscle, replacing aged heart cells. They know what they are and where they belong.

And because they are biologically very young and healthy, as they divide, they will gradually replace your older, less vigorous cells. In a year or so, you’ll have a heart that, except for its normal adult size, is very much like the heart you had as a child.

This Is Not Some Pipedream... It’s Happening TODAY

This isn’t just a nice story about some distant tomorrow. It’s a story about now. It has already been done to restore youth to animals. And I personally have undergone Steps 1 through 4, where very young heart-muscle cells were derived from my rather old skin cells.

But instead of simply telling you about my experience, I can show you something more fun—something that may knock you out of your chair (or off the treadmill, if you’re reading this at the gym).

While stored in a laboratory in Alameda, California, my newly developed heart cells—with no help or guidance or encouragement from anyone—assembled themselves into an actual, beating heart muscle. Thump-thump. Thump-thump. Thump-thump. Thump-thump. The cells know what to do.

Skin cells

It’s a bit personal, but it’s too wonderful not to share. Here is the beating of a somewhat old man’s very young, standby heart muscle. It’s mine. Living in the here and now, it’s a piece of me 64 years ago.

If I ever need them, the beating cells you just watched can be injected back into my body to repair the damage of a heart attack.

They’re my cells, carrying only my DNA, so my immune system won’t reject them. Instead, it will say, “Welcome home, kids. Now get to work.” But, for a reason I’ll explain, today I would have to go to all the way to Japan for the youth-restoring procedure.

How much would the richest man in the world pay for a perfectly functioning, youthful heart?

And he’s only one customer.

What’s Kept Life-Extension Biotech in the Shadows?

Life-extension technology is accelerating despite a needless and sometimes tragic handicap: US government regulations left over from the 1930s.

For now, what medical researchers can legally do for wealthy people in Japan is simply against the rules in the US—even though 10 or 15 years from now, millions of Americans will be getting it done at hometown US hospitals. Or even at Walmart clinics.

US law says: it is illegal; it’s a go-to-jail crime, to market a life-saving drug or procedure before it has undergone the FDA approval and licensing process. And that can take a decade or longer and cost the developer hundreds of millions of dollars.

Meanwhile, thousands, even millions, of people are left to suffer. Therapy after therapy, many die while waiting for the FDA’s outdated legal ritual to play out. It happens every day: someone dies because FDA officials haven’t quite finished giving him permission to stay alive.

If electronics were subject to FDA-style regulation, the first Apple iPhone would still be just a rumor. And Apple might be in legal hot water for letting the rumor happen.

Evil Walnut Drug

Here’s a low-stakes example of how crazy drug regulation in the US can get.

In 2010, Diamond Foods, a California-based company that packages nuts you can buy at the grocery store, advertised that walnuts help prevent heart disease.

Any doctor would rate that message as sound. But what Diamond Foods got from the FDA was a threat-filled letter telling them to button their lip about heart disease because...

... your walnut products are drugs within the meaning of section 201 (g)(1)(B) of the Act [21 U.S.C. § 321(g)(B)]. Your walnut products are also new drugs under section 201(p) of the Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for the above referenced conditions.

For Diamond Foods, backing off was easy, since they’re not really in the drug business. They’re in the business of putting nuts into cans. But for biotech companies, it’s a different matter. The scientists and entrepreneurs in the US who are developing therapies to let you enjoy your 100th birthday know that regulatory craziness is a fact of life.

One result is way too much silence. Every time a biotech company talks to the public, it risks bumping into a hair-trigger regulation. The fines, lawsuits, asset seizures, and court orders could add up to business disaster. It’s safer to keep working and keep quiet.

That’s why interviews, press releases, and shareholder communications are never prepared by scientists. They’re prepared by lawyers. And a lawyer’s goal is to keep the client out of trouble. Keeping you informed counts for nothing.

The practical consequence: a big flow of big news about life extension doesn’t reach the mainstream media—or you—until it’s very old news. Counterproductive regulation keeps it trapped behind the closed doors of the cutting-edge biotech companies that are developing it. It’s blacked out for the general public and even for many of the investment banking firms that think they’re keeping up with biotech.

Getting Ready to Turn On the Light

Catching that profitable, life-extending information early and bringing it to the readers of Transformational Technology Alert early is what I do. I have some big advantages that keep me well ahead of the pack.

I work exclusively in the information business; everything I do happens inside the First Amendment’s zone of protection. Because I don’t develop or sell pharmaceuticals, I don’t get entangled in the FDA regulatory net. That leaves me legally free to tell you everything I learn, and tell you as soon as I learn it.

I learn plenty because I’m the person top biotech researchers are comfortable talking to. I speak their language, and—more important than that—I’m safe. They know from long experience that I understand the heavy regulation they live under, and I respect how careful they need to be.

And I share their passion for life extension. They meet me with openness because I meet them with the ear of a scientist, not the notepad of a lawyer or the gotcha attitude of a regulator. What they’re not ready to show anyone else, they’ll show me without waiting.

That’s how, again and again, my readers are first to learn what Nobel-Prize-winning scientists have just discovered about extending healthy lifespans and controlling cancer, heart disease, arthritis, Alzheimer’s, and the other diseases of aging.

Some conversations are private tête-à-tête alongside biotech conferences. Others happen in the lab or over lunch. Some of the most fruitful come later in the day, with a glass or two of Guinness. Wherever or however, I’m able to reach the geniuses who are discovering how you can stay very healthy as you grow very old because our conversations are strictly off the record, with no risk of regulatory blowback.

My Strategy to Find the Money-Makers

Over the last 20 years, I’ve seen hundreds of biotech companies from the inside. Nearly every one of them was the love child of a scientific genius. But too many of them were money pits—all science and no business. What I search for, for myself and for my readers, are money fountains.

A few points I check before I consider investing:

  • Is the company’s science valid, or has it already been discounted by research elsewhere? Some companies are chasing a fox that died last week.

  • Are the people running the company serious about profit, or are they just looking for someone to pay for their pet science project?

  • If the company brings its therapy to market, will it make a big, revolutionary difference to human health or just a marginal improvement? (Small profits aren’t my goal.)

  • Will the company’s therapy invite rapid adoption—and rapid profit—by cutting the cost of treatment and care?

  • Even if the company has shown that its therapy works in test animals, what does that really say about the likely results for people? (Some biochemical systems in mice are nearly identical to those in humans. Others are known to be very different.)

  • How much experience does management have in nurturing a small, lightly funded venture and turning it into a multi-billion-dollar asset?

Evaluating the answers has already put serious money into the pockets of Transformational Technology Alert subscribers. A few of the richest examples...

The Cellular Rejuvenator

20 years ago, only because I happened to be in the right tailor shop in Menlo Park, California, I met a PhD cellular biologist already known as the father of regenerative stem cell medicine. He’d just read an editorial on genetic research I’d written for the Wall Street Journal.

In 2008, I learned that the same individual had transferred patents for the most promising stem cell therapies into a newly organized company. I wanted to learn more. After some drill-down talks with this biotech pioneer about how to turn the patents into money-making products and processes, I wanted in.

In that same year, I recommended the company to my readers when it was selling at $0.68 per share. Now the stock is trading near $3.75. That’s a 550% gain. Recently I suggested that readers sell a few shares to recoup their cost. From here on, it’s pure profit.

And I expect a lot of it. A river of profit. I’ll be telling readers of Transformational Technology Alert when to cash out and collect the money.

This company developed and still owns the technology that produced my brand-new, beating heart muscle cells. That same technology can be applied to generate youthful cells of any kind—eye, liver, lung, kidney, bladder—anything. There seem to be no limits to what it can do... or to the money it can make.

The cellular biologist and his company are currently overseeing clinical trials of their stem-cell therapies for macular degeneration and spinal cord injuries. Repairing spinal cord injuries (helping people walk again) would be a spectacular, joyous success in a minuscule market. Reversing macular degeneration would be a welcome success in a giant market of paying customers.

Antibiotics That Won’t Wear Out

Watch out! Here comes another one!

Every minute, billions of bacteria land on and in you. You don’t notice, because most of them are promptly killed by the billions of microscopic structures present on your skin and elsewhere in your body called defensins.

I’m sure you’ve seen the scare stories about flesh-eating bacteria and other superbugs that resist all antibiotics. The stories are true... as far as they go.

It’s no fiction that bacteria are developing resistance to penicillin and to the rest of the conventional antibiotics Big Pharma sells. Those drugs work by poisoning bacteria—and with enough time, bacteria can mutate to tolerate any poisonous drug your own body can tolerate.

Your natural defensins work differently. They don’t poison anything. They’re street fighters. They puncture the cell walls of the bacteria they touch. Bacteria can’t develop resistance to being torn open, so defensins will never stop working.

For me, just understanding the science is a big reward. But the science gets even more interesting when there’s some money in it.

Natural defensins are the model for an entirely new type of antibiotic. In a day not too far off, when conventional antibiotics have been reduced to mere BB guns, synthetic defensins will be delivering the antibacterial fire power needed to keep surgery and trauma patients alive.

In 2011, a friend in the nuclear research industry alerted me to an obscure project developing synthetic defensins to back up the ones the body produces naturally. A year later, when I learned the key patents and other intellectual property were being acquired by this company, my antennae went up.

Conventional antibiotics are a $40 billion per year industry. As those products grow stale and ineffective, the money is going to flow toward defensin-based therapies. Because it has the right technology, I expect this firm to be the biggest beneficiary.

After some heart-to-heart talks with the company’s management and senior researchers, I recommended the stock to readers of Transformational Technology Alert at $1.88. Later, I suggested selling a fraction of the shares at $2.93, for a 56% profit in 9 months. Selling smart is just as important as buying smart.

You can read more about both of the above-mentioned companies—including their full names and ticker symbols—in my just-released special report, World-Changing Biotech Stocks to Own Now. More on that in a minute.

More Early Winners

A universal flu vaccine. This company knocked on my door in 2010. They wanted to show me how their anti-viral therapy could beat the socks off the product of a biotech innovator I was already covering.

This firm is developing a once-and-for-all, universal flu vaccine. It will stop all strains of influenza and end the need for annual flu shots. Everyone on the planet will want their product, which would prevent 10 billion or so days of individual human misery every year.

I recommended the company to Transformational Technology Alert subscribers and after holding the stock for 13 months, suggested selling one-fourth of the shares for a 54% profit.

An effective Parkinson’s treatment. Selling barely helpful treatments for Parkinson’s disease is a $2.1 billion per year industry. The company improved an existing Parkinson’s drug and then developed a technology to speed up the drug’s entry into the blood stream.

We bought the stock at $0.50 per share and have already sold a little at $0.76. In Transformational Technology Alert, I recommended holding on to the rest, for gains that should be much more serious. I’ll be watching for the right exit.

Targeting two major aging diseases. A former senior executive from Big Pharma who is a confidant of many years alerted me to this one.

This company is turning its research into the molecular workings of sigma-1 receptors (you’ve got them on the surfaces of all your cells) into treatments for glaucoma and Alzheimer’s.

In focusing on glaucoma and Alzheimer’s, the company is aiming at two big-money targets. Blindness is among the most feared disabilities. And the years of care demanded by its victims makes Alzheimer’s the costliest of all diseases—draining more from the US healthcare budget than even cancer or heart disease.

This company is one of our biggest winners. Subscribers who sold shares when I recommended realized a 230% profit.

I could tell you more about profiting from the almost daily advances in life-extension biotechnology... and I’d like to. That’s why I’m offering you a no-risk invitation to join the readership of Transformational Technology Alert.

Test It Today: Your No-Risk Invitation

In each monthly Transformational Technology Alert, I report on the rapid progress that hard science is making against age-related disease. Discoveries you can use for your own health. Fact-based company analysis for winning investment decisions. News most investors won’t hear until three or four years down the road, when it will be too late to earn the home run profits you’ll already have tucked into your pocket.

And in most months, I’ll send you one or more Special Alerts about research developments that just can’t wait. (Astounding things are happening at an astounding pace.)

The investment payoff from early knowledge is enormous—and the earlier the knowledge, the bigger the payoff. So when I learn something that can’t wait for the next monthly issue, I want to tell you about it now in a Special Alert while the news still has maximum value.

Here’s my no-risk invitation because I want you to become a subscriber.

Plugging into the profit-making information flow available only to subscribers of Transformational Technology Alert costs $950 per year. That’s less than you’re probably paying for the so-what investment news you get with your cable TV package.

Even so, I know you won’t want to commit to Transformational Technology Alert until I’ve proven to your satisfaction that it is worth much, much more than $950.

So I’m extending a no-risk invitation for you to share the opportunity I’ve found at the loveliest spot I know—the intersection of science and profit.

Subscribe now. That’s how you start.

Then look and see. Evaluate each monthly report and the Special Alerts. Track the investment recommendations.

Ask yourself every day, “Do I know far more now about the science of life extension than I knew before I subscribed? Do I see how radically different the healthcare industry is going to be? Am I turning this knowledge into money? Have I really set my foot on the path to my 100th birthday?

If along the way you decide that the realistic answers are “No,” a zero-cost exit will be wide open for you. Just tell me before you receive the fourth monthly edition and I’ll immediately hand you a full, 100% refund—the entire $950. No arguments, no foot dragging, no delays, not a penny held back. Just send me an email at subscribers@mauldineconomics.com and say “MONEY BACK, PLEASE. ALL OF IT. RIGHT NOW, THANK YOU.” Or call (877) 631-6311 and say the same thing.

We don’t get many cancellations, because the information I deliver to my subscribers about using and profiting from life-extension technology is real and it’s fresh. But when we do get a refund request, we act the same day. The refund reaches the subscriber’s credit card account three to four days later. And we part as friends.

Our refund policy never shuts down.

Even after you’ve received the fourth monthly Transformational Technology Alert, if you ever decide to cancel, just say so. You’ll get a full refund for the monthly issues you haven’t yet received. Again, no arguments, no talk-back, no need to explain. And no hard feelings. We’re adults.

Six Free Bonus Gifts

I don’t know how to make it easier for you to subscribe—and to learn, thrive, and profit. But here’s something extra. Accept this no-risk offer now, and I’ll welcome you to Transformational Technology Alert with six valuable—and absolutely free—bonuses.

Bonus #1:

World-Changing Biotech Stocks to Own Now

The Visionary’s Guide to Profits: 5 Must-Own Small Biotech Stocks That Could Change the World

Each of the companies analyzed in this report is far advanced in developing a biotechnology to stop a condition that destroys hundreds of thousands of lives every year and sucks up billions of dollars in treatment costs. The windfalls for shareholders in these select companies could be immense.

I introduced three of them above, and this report will give you the full details on all of them… including their names.

  • Must-Own Stock #1: Regenerative medicine that can slow and possibly even reverse aging. This company’s research focus is a type of adult stem cell with the power to grow into any type of human tissue. The related therapy requires no suppression of the patient’s immune system. This key player in its field owns well over 800 patents in stem cell medicine and is working on a vast spectrum of applications for its technology.

  • Must-Own Stock #2: The flu virus mutates constantly. That’s why you need a new flu shot every year—and why you can never be sure it will work. This company’s technology defeats influenza’s mutation strategy by attacking proteins that are present in every variety of flu virus. Once this innovation comes to market, no one who uses the company’s product will ever need to worry about the flu again.

  • Must-Own Stock #3: This company produces “fountain of youth” proteins that rejuvenate the cells of older mammals and extend their lives by more than one-third. The new treatment is already being used on livestock in Australia—with mind-boggling results. Now the company is adapting its technology to extend human lives as well.

  • Must-Own Stock #4: The potency of old-style antibiotics is slowly fading, as more and more bacterial strains develop resistance. Without something new to replace old-style antibiotics, even small wounds will be life-threatening, as they were before the advent of penicillin in the last century. This company has developed a radically different solution. It has turned naturally occurring peptides into super-warriors that rip into the surface membranes of bacteria—an attack that bacteria can never learn to resist.

My report gives you the full names, ticker symbols, and all the details about each of these companies, including technologies, management teams, and patents.


Bonus #2:

Anti-Aging Supplements I Use Now

Anti-Aging Supplements You Can Use Now

I am asked almost every day, “What supplements do you take to slow down your own aging and protect your health?” The short answer is that I take what science has shown is likely to work.

Even though much of the “healthy stuff” offered on the Internet or waiting on the shelves of retail outlets is useless, a select few of the scientifically researched supplements really do work.

In my eye-opening report, Anti-Aging Supplements I Use Now, you’ll learn what they are—the short list of powerful substances available now that can add a decade or more to your healthy years.

  • A so-called “vitamin” that’s actually a hormone. Almost every North American today is deficient in this substance that’s essential for health and longevity. A leading scientist in the field says individuals in the US and Canada could extend their lifespans by 10% by raising their levels of this substance... and they’d cut their lifetime medical costs by 20%.

  • A dietary component that was made to look like a bad guy less than 20 years ago—but recent research has found that it’s actually a hero. It opens blood vessels and reduces artery stiffness; it lowers high blood pressure and speeds up the metabolism to fight obesity and diabetes. The best part: You can find it right in your grocery store’s produce aisle...

  • A substance that’s already in your body but at levels that, after age 30 or so, are too low to fully support the efficient conversion of food into energy. Adding this natural substance to the diets of old test animals restored their tissues to the robust condition of juveniles.

  • Plus four more life-extenders to steer your aging into the slow lane: Resveratrol’s replacement (that actually works!)... the supplement that increases energy production in the brain and its perfect companion... and the most bioavailable form of a critical element in cellular energy production.


Bonus #3:

Free Sample of a Powerful Anti-Aging Supplement

You’ll receive a one-month supply of one of the substances you’ll read about in Anti-Aging Supplements I Use Now.

  • A clinically studied pure form of pterostilbene, the natural substance that has earned blueberries such a strong reputation as an ultra-healthy food.

  • A patented and clinically studied form of nicotinamide riboside (NR), a metabolic precursor of a substance that the mitochondria in your cells need for efficient and responsive energy production. NR occurs naturally in milk and other foods, but at levels that are too low in most people over age 30.

  • Thermally stabilized oxaloacetate, which in laboratory studies has been proven to increase lifespan in mammals by mimicking the life-extending effects of caloric restriction and protecting mitochondrial DNA.

* This supplement are only available to subscribers within the continental US.


Bonus #4:

Boosting Your Odds at the Big Casino

Changing the Odds at the Big Casino

Old-school cancer treatments—chemotherapy and radiation—can be almost as damaging to the patient as the disease itself.

Something much better is about to appear. Some morning in the not-so-distant future, a press release from a biotech startup is going to tell the world that cancer as we knew it is over. At that point, the $100 billion cancer-treatment industry will implode.

We got early glimpses of that scenario in 2015, when a new treatment at Memorial Sloan Kettering Cancer Center “melted” a 49-year-old woman’s breast cancer tumors... and when 24 of 27 leukemia patients in a new-drug study went into remission.

You’ll also learn:

  • How science can halt a cellular dead-end process that leads to cancer

  • Why controlled “cell suicide” is essential for your body’s well-being

  • The new face of cancer treatment: re-training the immune system

Read my report on the science of cancer and the #1 fact that’s revolutionizing oncology today.


Bonus #5:

My new, full-length ebook, The Methuselah Effect

The Methuselah Effect

The 1960s myth of a planet dying from over-population still has most people in its grip. It’s simply not true.

The Methuselah Effect documents how the spread of first-world technology and living standards always lead to lower birth rates and, with a delay, to shrinking populations. The result, which is already hitting Japan and most of Europe… and will soon reach the US, is a “gray tsunami” that puts a huge strain on governments committed to supporting the elderly.

The only way out: biotechnology that helps people stay healthy as they age, so that they can remain productive and self-sufficient for more years.

In my book, The Methuselah Effect, I discuss in depth the astounding therapies now in the making in US biotech labs.

  • Some are so sensational that they could fit into a science-fiction story.

  • Some extensions of traditional practices and reliance on naturally occurring substances.

  • And some could be helping you right now, as over-the-counter supplements, if you know about the few products that really work.

A must-read book for everyone who is interested in demographic trends and enjoying a longer, healthier life.


Bonus #6:

How to Join a Drug Trial

Changing the Odds at the Big Casino

Many new drugs that treat—or even cure—debilitating and life-threatening diseases have already been developed and are 100% ready to be used. But you can’t have them.

They’re not available to you yet because they’re still tangled in the FDA’s decade-long licensing process. You could die waiting.

So if you ever find yourself with a devastating medical condition that can only be helped by a drug that’s still caught up in the FDA traffic jam, your best strategy is to join a drug trial to get access to what you need.

In this special report, I discuss...

  • How drug trials work: Different phases of clinical trials, use of placebos, blind and double-blind studies; how patients are monitored and protected.

  • How to get in: Defining your condition; the best resources for finding a drug trial that is right for you

  • Stacking the deck: How to boost your chances of being accepted; what joining will get you

If you don’t need it now, put this report away in a safe place. If you or someone you know is ever diagnosed with a serious health condition, it could prove to be a lifesaver.

Build Wealth and Live Longer to Enjoy It

Accept my no-risk invitation to subscribe to Transformational Technology Alert and I’ll send you all six free bonuses immediately. (The supplement sample will be sent separately.)

The “no-risk” part of the invitation is real. If, for any reason, you later decide to cancel before your fourth monthly issue of Transformational Technology Alert, I’ll send you a full, 100% refund. Net cost to you: Nothing at all. ZERO. Resign your subscription even after your third monthly issue, and I’ll promptly send you a pro-rata refund.

(Yes, the six free bonuses really are a gift. If the unhappy day ever comes that I lose you as a subscriber, you’ll be welcome to keep all of your bonuses, with my compliments.)

On the other hand... while you continue your subscription, I’ll keep sending you valuable information you won’t find anywhere else—information that can bring you extraordinary profits from the good that biotechnology is delivering for mankind and that can extend your healthy years far beyond what most people expect for themselves.

I hope you’ll join us. I want you to receive the monthly flow of biotech information and Special Alerts that could extend your healthy years into the triple digits and put even more digits on your brokerage statement.

Click Here To Get Started Now

Sincerely,

Patrick Cox
Patrick Cox
Editor of Transformational Technology Alert
Mauldin Economics

P.S. Will I really get there? Of course, I can’t know for sure. But calculation tells me, “Yes, I will.” It’s no longer a fantastic thought that I could reach my 100th birthday.

With little more than the simple science that today is taught to junior high school students, human lifespans nearly doubled between 1850 and 2000. It was a wonderful start. It was the work of medical pioneers and true heroes of science we should remember and honor. But it would be a stretch to call the progress methodical.

Today’s project is far more deliberate, and the pace far more rapid. The next doubling in human lifespans won’t take anything like 150 years. Science is now drilling to the very bottom of the well of biological understanding to chart, molecule by molecule and step by step, the internal choreography of the cellular dance. What they are finding can keep you alive and make you rich.

So much has already been discovered. And hardly a day goes by when I don’t hear something fresh to celebrate from the cellular biologists and biochemists who are learning to disarm the mechanisms of aging.

They’re moving forward so rapidly because now they know exactly what they’re searching for. And they’re equipped with modern laboratory instruments and computing tools that can pick apart a molecular puzzle one atom at a time in just seconds. The science of life extension has learned to zoom.

Yes, it’s real. And yes, I really am planning on having my 100th birthday party. A catered affair, likely, and certainly with live music. There will be so very much to celebrate. I hope the neighbors won’t mind if the party runs late. In any case...

You’re invited.

Click Here To Get Started Now


Copyright © 2016 Mauldin Economics. All Rights Reserved.